Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS?
Level V
Where this comes from
- Record sourced from PubMed, PMID 24583981.
- Also identified by DOI 10.1038/ki.2013.549.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A soluble proteinuric substance has been postulated as a cause of primary focal segmental glomerulosclerosis (FSGS), and one candidate soluble urokinase receptor (suPAR). Evaluation of published results shows that serum suPAR determinations by current methodology do not reliably distinguish FSGS from other proteinuric glomerular diseases and serum suPAR cannot currently be considered a valid biomarker for primary or secondary FSGS. However, this should not discourage further research on potential roles of suPAR in proteinuric renal disease, including FSGS.
Medical subject headings
- Glomerulonephritis
- Glomerulosclerosis, Focal Segmental
- Nephrotic Syndrome
- Receptors, Urokinase Plasminogen Activator